前沿生物跌7.55% 2020上市见顶两募资共20.44亿元

Group 1 - The core point of the news is that 前沿生物 (Frontier Biotech) is currently experiencing a decline in stock price, with a closing price of 20.07 yuan and a drop of 7.55% [1] - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial public offering (IPO) of 89.96 million shares, accounting for 25.01% of the total shares post-issue, at a price of 20.50 yuan per share [1] - The highest stock price recorded since the IPO was 35.53 yuan, indicating that the stock is currently in a state of decline [1] Group 2 - The total amount raised from the IPO was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs for the IPO (excluding VAT) were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Group 3 - On September 22, 2022, Frontier Biotech announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [2] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [2] - The total fundraising from both the IPO and the subsequent issuance amounts to approximately 2.044 billion yuan [3]